IP protection, page-8

First 8 Last

Share
Profile

Follow
reon1

1,536 Posts.

510

25/08/24

16:56

Post #: 75363411
Share

Originally posted by Lastly: ↑

@reon1 patents issued are patents in the eyes of the law unless somebody can show one infringes on a pre existing one.

Long story short, Dr David Morris, head of the oncology unit of St George's Hospital in Sydney and professor and research scientist at the University of NSW noticed in a test that mpl was having an effect on human cancer cells, so he and a team at UNSW did some deep research to check out if this was just a minor and temperary aberration as happens with some molecules upon cancer or if there was something more important going on, and lo and behold it turned out that monepantel was upregulating autophagy through its effect on the complex mTOR signalling pathway system which was inhibiting the growth of the cancer cells - they had a brand new mTOR inhibitor on their hands!!! Now the question was, could a way of making it a useful treatment be developed? Well, after many years and twists and turns that would put a classic epic to shame, we now have a vert useable and stable mTOR inhibitor pill with minimal side effects.

Here's one listing of the patents and note that more are pending. They are listed under the Pitney Pharmaceuticals name, as that was the company which was created for developing monepantel and a couple of other now discontinued oncology drug and then taken over by PharmAust soon after in late 2013 iirc.

https://patents.justia.com/assignee/pitney-pharmaceuticals-pty-limited

Expand

Great summary, thanks Lastly!

PAA Price at posting: 17.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

OJC

SPC to merge with Original Juice Co and Nature One Dairy

There are more pages in this discussion • 2 more messages in this thread...

First 8 Last

Add PAA (ASX) to my watchlist

(20min delay)
Last 19.0¢		Change 0.000(0.00%)		Mkt cap ! $92.46M

Open	High	Low	Value	Volume
19.0¢	19.5¢	18.5¢	$177.2K	929.4K

Buyers (Bids)

No.	Vol.	Price($)
5	499621	19.0¢

Sellers (Offers)

Price($)	Vol.	No.
20.0¢	70000	1

View Market Depth

No.	Vol.	Price($)
5	499621	0.190
6	198481	0.185
8	508662	0.180
10	407474	0.175
8	151233	0.170

Price($)	Vol.	No.
0.200	70000	1
0.205	88150	4
0.210	308355	7
0.215	254820	7
0.220	664543	8

Last trade - 16.10pm 02/10/2024 (20 minute delay)

PAA (ASX) Chart

IP protection, page-8

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

SPC to merge with Original Juice Co and Nature One Dairy

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

IP protection, page-8

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

SPC to merge with Original Juice Co and Nature One Dairy

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News